Molecular Imaging PhD: Developing and evaluating targeted radiotracers

Molecular Imaging PhD: Developing and evaluating targeted radiotracers

Checked: 5 November 2026 (Asia/Shanghai)
Decision label: Consider if synthesis-led radiochemistry is your fit; verify the live application and degree route.

Quick Decision

This is a coherent, salaried doctoral role for a chemist who wants to build targeted radiotracers and follow them from synthesis and radiolabelling into cell-based and animal imaging work. The strongest fit is a candidate with substantial hands-on preparative organic synthesis who is willing to work with open radioactive substances and in-vitro/in-vivo methods. The group’s recent papers show related radiochemistry, conjugation and biological-evaluation experience. The vacancy information states 65% employment for three years, third-party project funding, TV-L pay and VBL pension, with a deadline of 18 December 2026 at 00:00 Europe/Berlin.

There is a current-status caveat: on 5 November, the employer’s search result returned this exact doctoral vacancy, but another rendering of the live list did not show the role and the individual record could not be fetched by the browser reader. The application form’s current acceptance is therefore unverified. The listed midnight deadline is at the start of 18 December unless the employer confirms a different interpretation; in winter it corresponds to 07:00 on 18 December in China. Check the portal and contact the employer before investing heavily in an application. The salary grade/step, specific doctoral award, named supervisors, grant identity and project target also remain unresolved. Current employer vacancy listing, captured official vacancy record

Research Problem and Doctoral Work

What Is Unsolved and Why It Matters

The central development challenge is to create a molecularly targeted radiopharmaceutical whose chemistry and biological behavior work together: the targeting vector must retain affinity, the chelator and radiometal complex must label efficiently and remain stable, and the finished radioligand must reach its target with useful distribution and clearance. Diagnostic positron-emitting labels and therapeutic beta emitters can be paired in a theranostic strategy, but each isotope and vector imposes different chemistry, imaging, dosimetry and supply constraints. Recent EMA analysis describes a substantial rise in radiopharmaceutical trials and identifies new radionuclides, targeting vectors and regulatory demands as active areas; OECD-NEA analysis adds production, logistics and infrastructure constraints. These trends establish a live field, not a guarantee that a particular tracer will translate clinically. EMA radiopharmaceutical horizon report, OECD-NEA medical isotope supply report

Work, Methods, and Potential Outputs

The vacancy describes development of new multimodal radiotracers or targeted radioligands. The listed work includes preparing and characterizing chelators, linkers and labeling precursors; radiolabelling with positron and beta emitters; characterizing chelators, metal complexes and radioligands; carrying out in-cellulo binding studies; and assessing in-vivo pharmacokinetics through molecular imaging and ex-vivo biodistribution. The group’s own workflow similarly runs from small-molecule or peptide targeting vectors through chelator/tag attachment and radiolabelling to in-vitro binding and in-vivo/ex-vivo evaluation. This alignment makes the role unusually concrete at the methods level, although the advertised record does not name the biological target, cancer type, radionuclide, imaging modality, model, or final milestone. Ask which components are already fixed and which the doctoral researcher is expected to choose. Molecular Imaging and Radiochemistry group, group research themes

Potential outputs could include reproducible synthesis and radiolabelling protocols, validated chemical and radiochemical characterization, comparative binding or stability results, and a preclinical imaging/biodistribution dataset. These are reasonable inferences from the advertised methods, not promised deliverables. The project’s technical bottlenecks are likely to include radiochemical yield and purity, stability in biologically relevant conditions, target-specific binding, pharmacokinetics and the limited window imposed by isotope half-life. Ask about planned controls, failure criteria, model access and whether isotope availability constrains the experimental timetable. A 2026 EANM recommendation on alpha-emitter dosimetry is useful context for the broader theranostic field, but the vacancy itself names positron and beta emitters rather than an alpha-emitter work package. EANM alpha-emitter dosimetry recommendations

School, Programme and Field Context

The post sits in the Medical Faculty Mannheim of Heidelberg University and at University Medical Center Mannheim, within the Clinic for Radiology and Nuclear Medicine. Heidelberg reports Medicine at #34 globally and #2 in Germany in the 2026 QS subject ranking. That is a positive institutional signal, but it is not a ranking of this faculty’s doctoral pathway, the local lab or the specific project. For this decision, the relevant evidence is the group’s methods, supervision and facility access. Medical Faculty Mannheim directory, Heidelberg Medicine in QS 2026

The Medical Faculty Mannheim offers a doctorate leading to Dr. sc. hum. Its rules normally require a relevant master’s or equivalent, above-average degree performance, a written predoctoral thesis and a programme usually totaling 300 ECTS. For this route, foreign degrees require a ZAB assessment; degrees from China, India and Vietnam also require APS, and proof of language proficiency is listed when the applicant’s native language is neither German nor English. The faculty describes the thesis as usually about three years of full-time work and requires structured training for candidates admitted since 2022. Heidelberg’s general doctoral-enrolment page says enrolment normally continues through the doctorate, subject to possible exemptions for University or University Hospital employees. None of these pages confirms that this vacancy leads to the Dr. sc. hum. award or whether an employee exemption applies. Dr. sc. hum. requirements, doctoral enrolment rules

The three-year contract at 65% and the faculty’s usual three years of full-time thesis work warrant a direct timeline discussion. They do not establish that completion is impossible: the contract percentage and thesis norm are different measures. Ask how much of the 65% appointment is protected research time, what milestones are expected, how committee review is handled and whether an extension is possible if the examination process runs beyond funding.

Supervisor and Lab Assessment

The team roster names Prof. Björn Wängler as Professor of Molecular Imaging and Radiochemistry, Prof. Carmen Wängler as head of Biomedical Chemistry and Dr. Patrick Cieslik as a research staff member. The captured job record names Cieslik as scientific contact. These facts identify a credible local team, but the roster and vacancy do not state the formal principal supervisor, daily mentor, co-supervisor arrangement or meeting cadence. Group team roster, faculty directory

Supervisor Research Directions

The group’s pages describe multimodal theranostics, PET tracers, nanoparticle imaging, radiochemistry and preclinical evaluation. The clinic describes a GMP-compliant hot laboratory producing individualized radiopharmaceuticals, including immuno-PET tracers. A separate translational imaging unit is also listed in the wider clinic. These pages show an institutional research environment, but they do not promise that the doctoral project will use the GMP facility or receive clinical-study access. Confirm actual facility allocation and collaborators with the supervisors. Group research page, clinic research and innovation

Recent Important Publications

• Cieslik et al., JACS Au (2025): the team-associated study uses light-triggered synthesis of 161Tb-labelled onartuzumab, followed by biochemical and cell-binding work, imaging, biodistribution, pharmacokinetics and a gastric-cancer animal model. It demonstrates an integrated radiochemistry-to-preclinical pipeline, but remains preclinical and does not establish patient benefit. Paper
• Cieslik, Klingler, Nolff and Holland, Chemistry—A European Journal (2024): 177Lu-bispidine-trastuzumab work combines chelator/metal-complex chemistry, light-triggered antibody conjugation and cell/in-vivo targeting. It is a direct methods precedent for chelator and radioligand development, while its HER2/trastuzumab target should not be presumed for the new role. Paper
• Bleher, Cieslik and Comba, Dalton Transactions (2025): a review of bispidine coordination chemistry frames rapid complex formation, metal selectivity, stability and kinetic inertness as design constraints for medical probes. This is a useful synthesis of the group’s chemistry context, not a new tracer experiment. Review
• Cieslik, Björn Wängler and Carmen Wängler, Journal of Medicinal Chemistry (2025): a review discusses alpha-emitter radiopeptides, their therapeutic rationale and remaining challenges. It supports the team’s field breadth but does not imply that the vacancy focuses on alpha therapy. Review
• Cieslik et al. (2026): bispidine–lanthanide near-infrared probes extend the group’s imaging chemistry toward cell testing and in-vivo zebrafish imaging. This is adjacent evidence of imaging-probe capability, not a stated radiotracer deliverable. Paper record

The set suggests a productive blend of coordination chemistry, radiolabeling and biological evaluation, with reviews that consolidate technical constraints. It is not evidence about publication expectations, individual authorship opportunity, PhD completion rates or supervision quality. Ask how prior students divide experimental work and what publication plan is realistic for a three-year, 65% appointment.

Lab, Resources, and Collaboration Environment

The group outlines a complete sequence from synthesis to preclinical characterization, and the broader clinic reports a hot lab and nuclear-medicine research infrastructure. The faculty sits in an interdisciplinary environment where chemistry, radiology, nuclear medicine, biology and molecular imaging can intersect. Nevertheless, the public pages do not identify the project’s isotope supply, scanner time, animal models, cell lines, collaboration agreements or access priority. The institutional capacity should be treated as an opportunity to verify, not as a guaranteed resource. Group workflow, clinic infrastructure

Funding, Application, and Living Cost

The captured employer record describes one position at 65% of regular weekly hours, fixed for three years and funded by a third-party research project. It states TV-L pay and VBL supplementary pension. The official employer search result returned the exact role on 5 November as part-time, fixed-term and Doctorand/PhD; however, the live page rendering later omitted the vacancy card, and the detail page was inaccessible through the reader. Treat the role as listed on the checked date, but confirm that the application link is still accepting submissions. Employer search result, official individual record

The stated deadline is 18 December 2026 at 00:00 (Europe/Berlin). That timestamp ordinarily means midnight at the start of 18 December, so a prudent applicant should aim to submit by 17 December and ask the employer to confirm. At that date Berlin is on CET (UTC+1), making the equivalent 23:00 UTC on 17 December and 07:00 in China on 18 December. The vacancy information does not provide a complete document checklist; check the employer portal and ask the listed contact rather than assuming that a CV alone is enough.

No tariff group or experience step is stated. The official TV-L table effective April–December 2026 lists E13 step 1 at €4,759.37 per month full-time; a 65% calculation would be about €3,093.59 gross/month only if this position is E13 step 1. That is a transparent benchmark, not the advertised pay. Taxes, social-insurance deductions, family/tax status and any special payments determine take-home pay. Ask HR to give the actual grade, step, gross amount, pension treatment and leave terms in writing. Official TV-L table, April–December 2026, official January–February 2027 table, TV-L agreement page

Mannheim’s student guidance gives an €850–1,000 monthly budget, including rent estimates of €250–450 and health insurance of €60–200. Student accommodation lists example rooms/apartments around €320–560, commonly with utilities. These figures can help with early planning but should not be directly compared with employee gross salary: an employee has different health/social insurance deductions, and student housing eligibility and vacancies are uncertain. Budget for current private-market rent and ask whether the employer provides relocation support or staff accommodation information. Mannheim living-cost estimate, student accommodation listings

Applicant Fit and Preparation

Required Background and Skills

The captured vacancy requires a completed Diploma/MSc in Chemistry or a related discipline, solid practical preparative organic synthesis, and readiness to work with open radioactive substances and carry out in-vitro/in-vivo studies. It describes interdisciplinary motivation as desirable. Peptide synthesis, chelator chemistry and coordination chemistry are advantageous, not listed as hard prerequisites. The post does not specify a German-language threshold or nationality restriction; absence from the record is not confirmation that no employer, visa or doctoral-admission conditions apply. Official vacancy record

Preferred Experience and Suggested Preparation

In an application, show specific examples of synthesis ownership: how you planned a route, optimized a difficult step, purified and characterized the product, assessed reproducibility and documented safety. If you have peptide synthesis, metal coordination, radiochemistry, cell assays, imaging or animal experience, state your actual role and training level. Do not inflate adjacent experience into radiation authorization. Read the team’s recent radiotracer papers and be ready to discuss how chelator stability, labeling kinetics, vector affinity and biodistribution could be evaluated. The German Radiation Protection Ordinance governs work with unsealed radioactive materials; ask what institutional training, personal dosimetry, medical checks and authorization are required before lab work. Radiation Protection Ordinance, recent 161Tb study

If the Dr. sc. hum. route applies, plan well ahead for foreign-degree assessment; Chinese, Indian and Vietnamese graduates also face APS requirements under the faculty’s listed process. The job and doctoral admission are separate decisions, and the vacancy does not state language documentation. Ask the doctoral office and employer to clarify exactly what is needed and when. Faculty doctorate requirements

Next Actions and Questions to Verify

Before Applying

1. Check the application link today. Does the employer’s form for vacancy 5317 still accept files? Is 18 December 2026 at 00:00 Europe/Berlin the start of the date, and what local system time controls receipt?
2. Check degree-route eligibility. Which faculty and title award the doctorate? Does the applicant’s degree meet the relevant master’s/ECTS/grade requirements, and are ZAB, APS, translations, language proof or export-control documents required?
3. Submit before the risky timestamp. If proceeding, treat the close as the start of 18 December and target completion by 17 December. Ask whether references, transcripts, a motivation letter or other documents are required.

At Interview

1. What target, disease context, vector, chelator/linker, radionuclide and imaging modality define the project? Which parts are settled, and which can the candidate shape?
2. What are the planned milestones and decision criteria for synthesis, radiochemical purity/stability, cell binding, imaging, pharmacokinetics and biodistribution?
3. Who is the formal supervisor, day-to-day mentor and co-supervisor? How often will progress be reviewed, and what support is available for doctoral training and writing?
4. Which specific hot-lab, isotope supply, imaging, cell-biology and animal facilities are committed? What radiation-safety, occupational-health and animal-training steps precede work?

Before Accepting an Offer

1. What are the exact TV-L group, step, 65% gross monthly salary, leave, annual payment, VBL and other benefits, start date and probation period?
2. Which third-party grant supports the position, is the full three-year salary committed, and can funding or employment extend if thesis examination takes longer?
3. Which doctoral award and faculty apply; what enrolment, semester-fee and structured-training rules apply, and how does the 65% contract support the faculty’s expected thesis timeline?
4. For an international hire, what visa, payroll/insurance and relocation assistance is available, and are there any language or export-control conditions?

Evidence and Sources

Vacancy, Group, and Faculty

• Current employer search result; individual employer vacancy record
• Molecular Imaging and Radiochemistry overview; research themes; team roster
• Older group vacancy page (shows a distinct expired 2024 notice); Medical Faculty directory; clinic research and innovation
• Dr. sc. hum. route; Heidelberg doctoral enrolment
• QS 2026 subject placements reported by Heidelberg

Funding and Living Costs

• TV-L table, April–December 2026; TV-L table, January–February 2027; TV-L agreement and current tables
• University of Mannheim student budget estimate; Studierendenwerk accommodation examples

Papers and Field Context

• Cieslik et al., 161Tb-labelled antibodies (2025); 177Lu-bispidine-trastuzumab (2024)
• Bispidine coordination chemistry review (2025); alpha-emitter radiopeptide review (2025); NIR bispidine–lanthanide probe paper (2026)
• EANM alpha-dosimetry recommendations; radiotheranostic landscape review; EMA horizon-scanning report; OECD-NEA isotope-supply report
• German Radiation Protection Ordinance; EANM workforce survey